Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Walt Disney Co (DIS) Price & Performance

Crispr Therapeutics AGTrade
Walt Disney CoTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Walt Disney Co — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Walt Disney Co trades at $103.47 (market cap $178.76B). The key difference: Walt Disney Co is far larger — about 34.2× Crispr Therapeutics AG's market cap, and Walt Disney Co pays a 1.45% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPDIS
Market Cap
$5.23B$178.76B
Sector
HealthMedia
52-Week High
$76.78$118.86
52-Week Low
$44.34$92.40
Enterprise Value
$3.65B$219.62B
Volume
7,546,013
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

No Aura AI signal available yet.

Walt Disney Co

Disney (DIS) trades at $103.20, down 1.62% on the day, amid a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.06 exceeding estimates by $0.20. Revenue growth has been steady, reaching $94.43 billion in 2025, while net income surged to $12.40 billion. Analyst sentiment remains positive with a consensus price target of $126.00, representing a 22% upside. Recent news highlights advertising opportunities with major events like the Super Bowl and ongoing FCC regulatory challenges.

The outlook for Disney is favorable, driven by earnings momentum, strategic investments in parks and streaming, and a dominant position in entertainment. Key risks include regulatory disputes with the FCC, box office underperformance of recent films, and economic sensitivity. With a P/E of 21.35 and robust cash flow, the stock offers value for long-term investors despite near-term volatility.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS